Critical Contrast: Nexalin Technology (NXL) & Its Competitors
Nexalin Technology stands as part of a competitive group of 76 public companies within the "Electromedical Equipment" industry. This review juxtaposes Nexalin Technology against its peers in terms of risk, valuation, profitability, institutional ownership, dividends, earnings, and analyst recommendations.
Valuation and Earnings
Below is a comparative table detailing the revenue, earnings per share (EPS), and valuation of Nexalin Technology against its industry rivals:
| | Gross Revenue | Net Income | Price/Earnings Ratio |
|—————————|—————–|——————|———————-|
| Nexalin Technology | $110,000.00 | -$4.65 million | -1.36 |
| Nexalin Technology Competitors | $1.00 billion | $82.19 million | -7.21 |
Competitors in the electromedical equipment sector significantly outperform Nexalin Technology in both revenue and earnings.
Institutional & Insider Ownership
A deeper look into institutional and insider ownership reveals:
- Institutional investors hold 0.7% of Nexalin Technology, whereas 45.1% represents the industry average.
- Insiders possess 27.7% of Nexalin Technology shares, in contrast to the industry’s 14.9%.
Higher institutional ownership typically signals investor confidence in long-term performance.
Profitability
A profitability comparison between Nexalin Technology and its competitors:
| | Net Margins | Return on Equity | Return on Assets |
|—————————|—————|——————|——————|
| Nexalin Technology | -3,088.12% | -154.84% | -122.94% |
| Nexalin Technology Competitors | -152.14% | -47.47% | -5.34% |
Nexalin Technology exhibits substantially poorer profitability metrics.
Analyst Recommendations
Here is a breakdown of current analyst ratings and target prices:
| | Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|—————————|————–|————–|————-|——————-|————–|
| Nexalin Technology | 0 | 0 | 0 | 0 | N/A |
| Nexalin Technology Competitors | 248 | 767 | 2030 | 101 | 2.63 |
Analysts project a 24.54% potential upside in the sector, though Nexalin Technology is expected to have less favorable growth prospects.
Risk and Volatility
Assessing the risk and volatility:
- Nexalin Technology has a beta of 5.13, indicating that its share price is 413% more volatile compared to the S&P 500.
- Comparatively, its competitors have a beta of 12.49.
Summary
Industry competitors outperform Nexalin Technology on eight out of ten key metrics.
About Nexalin Technology
Nexalin Technology, Inc., headquartered in Houston, Texas, develops and designs neurostimulation products aimed at treating mental health issues in the United States and China.
For more financial insights and detailed analysis, follow our news updates.
Stay informed with Bloomberg.
